» Articles » PMID: 29187928

Hormone-receptor Expression Status of Epithelial Ovarian Cancer in Ibadan, South-western Nigeria

Overview
Journal Pan Afr Med J
Date 2017 Dec 1
PMID 29187928
Citations 5
Authors
Affiliations
Soon will be listed here.
Abstract

Introduction: Epidemiological evidence strongly suggests that steroid hormones are implicated in the pathogenesis of ovarian cancer. Estrogen receptor (ER) and Progesterone receptor (PR) are prognostic indicators for a number of epithelial tumors and may play the same role in ovarian cancers. This study aims to evaluate the expression of ER and PR in epithelial ovarian cancer (EOC) in an African population and compare it with other prognostic factors such as age, International Federation of Gynaecology and Obstetrics (FIGO) stage, grade and histological subtype.

Methods: Ninety cases of histologically confirmed EOC were reviewed. Immunohistochemistry was used to assess their ER and PR expression status and was then compared with other demographic variables using statistical methods, with level of significance set at p < 0.05.

Results: 30.2% and 8.3% of serous and mucinous carcinomas respectively were ER positive while 41.2% and 22.5% of both tumour types were PR positive. One of the two endometrioid carcinomas showed PR expression but neither were positive for ER. The only case of Brenner tumour in the series was ER positive but negative for PR. There was a significant association between ER and the histological subtypes (p = 0.042) while no significant association was found between PR expression and histological subtypes (p = 0.650). No significant association was found between hormone receptor status, age and stage of the EOC.

Conclusion: The study showed a lower ER expression in serous carcinoma compared to large cohorts from developed countries. Future translational studies could be used to determine response of EOC to endocrine therapy.

Citing Articles

Protein Expression in Epithelial Ovarian Cancer and Associated Clinicopathological Factors in Uganda.

Okecha T, Abila D, Nabbale D, Katongole F, Yahaya J, Lukande R Obstet Gynecol Int. 2024; 2024:9527113.

PMID: 39502381 PMC: 11537748. DOI: 10.1155/2024/9527113.


Effects of the Overexpression of Progesterone Receptors on a Precancer p53 and Rb-Defective Human Fallopian Tube Epithelial Cell Line.

Chang Y, Wu K, Wang K, Ding D Int J Mol Sci. 2023; 24(14).

PMID: 37511582 PMC: 10380282. DOI: 10.3390/ijms241411823.


Prognostic value of β-Arrestins in combination with glucocorticoid receptor in epithelial ovarian cancer.

Ryu J, Shin H, Kim H, Han G, Kim J, Lee H Front Oncol. 2023; 13:1104521.

PMID: 36969037 PMC: 10036403. DOI: 10.3389/fonc.2023.1104521.


Estrone-Conjugated PEGylated Liposome Co-Loaded Paclitaxel and Carboplatin Improve Anti-Tumor Efficacy in Ovarian Cancer and Reduce Acute Toxicity of Chemo-Drugs.

Tang H, Xie Y, Zhu M, Jia J, Liu R, Shen Y Int J Nanomedicine. 2022; 17:3013-3041.

PMID: 35836838 PMC: 9274295. DOI: 10.2147/IJN.S362263.


Therapeutic options for mucinous ovarian carcinoma.

Gorringe K, Cheasley D, Wakefield M, Ryland G, Allan P, Alsop K Gynecol Oncol. 2020; 156(3):552-560.

PMID: 31902686 PMC: 7056511. DOI: 10.1016/j.ygyno.2019.12.015.

References
1.
Ho S . Estrogen, progesterone and epithelial ovarian cancer. Reprod Biol Endocrinol. 2003; 1:73. PMC: 239900. DOI: 10.1186/1477-7827-1-73. View

2.
Kommoss F, Pfisterer J, Thome M, Schafer W, Sauerbrei W, Pfleiderer A . Steroid receptors in ovarian carcinoma: immunohistochemical determination may lead to new aspects. Gynecol Oncol. 1992; 47(3):317-22. DOI: 10.1016/0090-8258(92)90133-4. View

3.
Odukogbe A, Adebamowo C, Ola B, Olayemi O, Oladokun A, Adewole I . Ovarian cancer in Ibadan: characteristics and management. J Obstet Gynaecol. 2004; 24(3):294-7. DOI: 10.1080/01443610410001660904. View

4.
Lee P, Rosen D, Zhu C, Silva E, Liu J . Expression of progesterone receptor is a favorable prognostic marker in ovarian cancer. Gynecol Oncol. 2005; 96(3):671-7. DOI: 10.1016/j.ygyno.2004.11.010. View

5.
Crum C, Drapkin R, Kindelberger D, Medeiros F, Miron A, Lee Y . Lessons from BRCA: the tubal fimbria emerges as an origin for pelvic serous cancer. Clin Med Res. 2007; 5(1):35-44. PMC: 1855333. DOI: 10.3121/cmr.2007.702. View